Table 5 Association between the B7-H4 expression groups and clinicopathologic factors in ovarian serous carcinoma
Clinicopathologic factors | B7-H4 negative group | B7-H4 positive group | p-value |
|---|---|---|---|
Residual tumor | Â | Â | 0.095 |
 Optimal | 47 (53.4) | 41 (46.6) |  |
 Suboptimal | 2 (20.0) | 8 (80.0) |  |
Tumor grade | Â | Â | 0.017 |
 1 | 10 (83.3) | 2 (16.7) |  |
 2 | 33 (44.0) | 42 (56.0) |  |
 3 | 19 (38.0) | 31 (62.0) |  |
Tumor stage | Â | Â | 1.000 |
 Early | 9 (47.4) | 10 (52.6) |  |
 Advanced | 40 (50.6) | 39 (49.4) |  |
Nuclear grade | Â | Â | 0.151 |
 Mild and moderate | 35 (52.2) | 32 (47.8) |  |
 Marked | 27 (38.6) | 43 (61.4) |  |
Mitosis | Â | Â | 0.558 |
 0–9/10 HPFs | 16 (51.6) | 15 (48.4) |  |
 10–24/10 HPFs | 27 (46.6) | 31 (53.4) |  |
 ≥ 25/10 HPFs | 19 (39.6) | 29 (60.4) |  |
Chemoresponse | Â | Â | 0.418 |
 Regressive disease | 22 (53.7) | 19 (46.3) |  |
 Stable/progressive disease | 21 (42.9) | 28 (57.1) |  |